Exatecan mesylate(CAS: 169869-90-3)

Exatecan mesylate (CAS: 169869-90-3) falls under the regulatory guidelines of REACH in the European Union, ensuring safe handling and use. It also requires classification and labeling according to GHS (Globally Harmonized System of Classification and Labeling of Chemicals), and may be subject to FDA and EPA regulations in the United States for pharmaceutical and environmental safety.

There are alternative compounds such as EDOX (Edoxaban mesylate) that can serve as synthetic analogs. Isomers of Exatecan (e.g., E- and Z-isomers) can also be used. Common alternative reagents include other alkylating agents like busulfan or melphalan, which can be used in place of Exatecan mesylate in various reactions.

Exatecan mesylate (CAS: 169869-90-3) is primarily used in cancer chemotherapy. Market trends show growing interest in its therapeutic applications in combination therapies. Research trends focus on optimizing its delivery systems and exploring its efficacy in treating resistant tumors. There is also a trend towards developing more potent analogs and derivatives for improved therapeutic outcomes.

Waste containing Exatecan mesylate (CAS: 169869-90-3) should be collected and stored in appropriate containers with proper labeling. Incineration or professional waste disposal services should be utilized for safe disposal. Environmental protection precautions include ensuring no spillage during handling and adhering to local and international regulations to prevent environmental contamination.